Loading...
•
Dec 31, 2022
Blueprint Medicines Q4 2022 Earnings Report
Blueprint Medicines reported fourth quarter and full year 2022 results.
Key Takeaways
Blueprint Medicines reported its Q4 and full year 2022 financial results, highlighting AYVAKIT's success as a standard of care for advanced systemic mastocytosis in the U.S. The company is nearing potential FDA approval of AYVAKIT for indolent SM and anticipates continued progress in clinical development programs.
Achieved $204.0 million in total revenues in 2022, including $111.0 million in AYVAKIT®/AYVAKYT® (avapritinib) net product revenues.
Continued progress toward regulatory approvals of AYVAKIT/AYVAKYT for indolent systemic mastocytosis, with FDA granting priority review of a supplemental new drug application and EMA validating a type II variation marketing authorization application.
Positive data from PIONEER trial of AYVAKIT in indolent systemic mastocytosis to be presented at the AAAAI Annual Meeting.
The company anticipates approximately $130 million to $140 million in AYVAKIT net product revenues for advanced SM and GIST in 2023, and $40 million to $50 million in collaboration revenues from existing collaborations.
Forward Guidance
Blueprint Medicines anticipates approximately $130 million to $140 million in AYVAKIT net product revenues for advanced SM and GIST in 2023, and $40 million to $50 million in collaboration revenues from existing collaborations. This guidance excludes revenue from the anticipated AYVAKIT indication expansion in ISM in mid-2023.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...